Research ExplorerPublicationsOutcome parameters for trials in atrial fibrillation: execut...

Outcome parameters for trials in atrial fibrillation: executive summary

Standard

Outcome parameters for trials in atrial fibrillation: executive summary. / Kirchhof, Paulus; Auricchio, Angelo; Bax, Jeroen; Crijns, Harry; Camm, John; Diener, Hans-Christoph; Goette, Andreas; Hindricks, Gerd; Hohnloser, Stefan; Kappenberger, Lukas; Kuck, Karl-Heinz; Lip, Gregory Y H; Olsson, Bertil; Meinertz, Thomas; Priori, Silvia; Ravens, Ursula; Steinbeck, Gerhard; Svernhage, Elisabeth; Tijssen, Jan; Vincent, Alphons; Breithardt, Günter.

In: EUR HEART J, Vol. 28, No. 22, 11.2007, p. 2803-2817.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kirchhof, P, Auricchio, A, Bax, J, Crijns, H, Camm, J, Diener, H-C, Goette, A, Hindricks, G, Hohnloser, S, Kappenberger, L, Kuck, K-H, Lip, GYH, Olsson, B, Meinertz, T, Priori, S, Ravens, U, Steinbeck, G, Svernhage, E, Tijssen, J, Vincent, A & Breithardt, G 2007, 'Outcome parameters for trials in atrial fibrillation: executive summary', EUR HEART J, vol. 28, no. 22, pp. 2803-2817. https://doi.org/10.1093/eurheartj/ehm358

APA

Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., Kuck, K-H., Lip, G. Y. H., Olsson, B., Meinertz, T., Priori, S., Ravens, U., Steinbeck, G., Svernhage, E., Tijssen, J., ... Breithardt, G. (2007). Outcome parameters for trials in atrial fibrillation: executive summary. EUR HEART J, 28(22), 2803-2817. https://doi.org/10.1093/eurheartj/ehm358

Vancouver

Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener H-C et al. Outcome parameters for trials in atrial fibrillation: executive summary. EUR HEART J. 2007 Nov;28(22):2803-2817. https://doi.org/10.1093/eurheartj/ehm358

Bibtex

@article{8ff6a359b00e4377bcf89b8daf190ce3,
title = "Outcome parameters for trials in atrial fibrillation: executive summary",
abstract = "Atrial fibrillation (AF), the most common atrial arrhythmia, has a complex aetiology and causes relevant morbidity and mortality due to different mechanisms, including but not limited to stroke, heart failure, and tachy- or bradyarrhythmia. Current therapeutic options (rate control, rhythm control, antithrombotic therapy, 'upstream therapy') only prevent a part of this burden of disease. Several new treatment modalities are therefore under evaluation in controlled trials. Given the multifold clinical consequences of AF, trials in AF patients should assess the effect of therapy in each of the main outcome domains. This paper describes an expert consensus of required outcome parameters in seven relevant outcome domains, namely death, stroke, symptoms and quality of life, rhythm, left ventricular function, cost, and emerging outcome parameters. In addition to these 'requirements' for outcome assessment in AF trials, further, more detailed outcome parameters are described. In addition to a careful selection of a relevant primary outcome parameter, coverage of outcomes in all major domains of AF-related morbidity and mortality is desirable for any clinical trial in AF.",
keywords = "Anti-Arrhythmia Agents/therapeutic use, Anticoagulants/therapeutic use, Atrial Fibrillation/economics, Catheter Ablation/methods, Costs and Cost Analysis, Electric Countershock/methods, Electrocardiography, Heart Failure/etiology, Hospitalization, Humans, Quality of Life, Randomized Controlled Trials as Topic, Stroke/etiology, Treatment Outcome, Ventricular Dysfunction, Left/etiology",
author = "Paulus Kirchhof and Angelo Auricchio and Jeroen Bax and Harry Crijns and John Camm and Hans-Christoph Diener and Andreas Goette and Gerd Hindricks and Stefan Hohnloser and Lukas Kappenberger and Karl-Heinz Kuck and Lip, {Gregory Y H} and Bertil Olsson and Thomas Meinertz and Silvia Priori and Ursula Ravens and Gerhard Steinbeck and Elisabeth Svernhage and Jan Tijssen and Alphons Vincent and G{\"u}nter Breithardt",
year = "2007",
month = nov,
doi = "10.1093/eurheartj/ehm358",
language = "English",
volume = "28",
pages = "2803--2817",
journal = "EUR HEART J",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "22",

}

RIS

TY - JOUR

T1 - Outcome parameters for trials in atrial fibrillation: executive summary

AU - Kirchhof, Paulus

AU - Auricchio, Angelo

AU - Bax, Jeroen

AU - Crijns, Harry

AU - Camm, John

AU - Diener, Hans-Christoph

AU - Goette, Andreas

AU - Hindricks, Gerd

AU - Hohnloser, Stefan

AU - Kappenberger, Lukas

AU - Kuck, Karl-Heinz

AU - Lip, Gregory Y H

AU - Olsson, Bertil

AU - Meinertz, Thomas

AU - Priori, Silvia

AU - Ravens, Ursula

AU - Steinbeck, Gerhard

AU - Svernhage, Elisabeth

AU - Tijssen, Jan

AU - Vincent, Alphons

AU - Breithardt, Günter

PY - 2007/11

Y1 - 2007/11

N2 - Atrial fibrillation (AF), the most common atrial arrhythmia, has a complex aetiology and causes relevant morbidity and mortality due to different mechanisms, including but not limited to stroke, heart failure, and tachy- or bradyarrhythmia. Current therapeutic options (rate control, rhythm control, antithrombotic therapy, 'upstream therapy') only prevent a part of this burden of disease. Several new treatment modalities are therefore under evaluation in controlled trials. Given the multifold clinical consequences of AF, trials in AF patients should assess the effect of therapy in each of the main outcome domains. This paper describes an expert consensus of required outcome parameters in seven relevant outcome domains, namely death, stroke, symptoms and quality of life, rhythm, left ventricular function, cost, and emerging outcome parameters. In addition to these 'requirements' for outcome assessment in AF trials, further, more detailed outcome parameters are described. In addition to a careful selection of a relevant primary outcome parameter, coverage of outcomes in all major domains of AF-related morbidity and mortality is desirable for any clinical trial in AF.

AB - Atrial fibrillation (AF), the most common atrial arrhythmia, has a complex aetiology and causes relevant morbidity and mortality due to different mechanisms, including but not limited to stroke, heart failure, and tachy- or bradyarrhythmia. Current therapeutic options (rate control, rhythm control, antithrombotic therapy, 'upstream therapy') only prevent a part of this burden of disease. Several new treatment modalities are therefore under evaluation in controlled trials. Given the multifold clinical consequences of AF, trials in AF patients should assess the effect of therapy in each of the main outcome domains. This paper describes an expert consensus of required outcome parameters in seven relevant outcome domains, namely death, stroke, symptoms and quality of life, rhythm, left ventricular function, cost, and emerging outcome parameters. In addition to these 'requirements' for outcome assessment in AF trials, further, more detailed outcome parameters are described. In addition to a careful selection of a relevant primary outcome parameter, coverage of outcomes in all major domains of AF-related morbidity and mortality is desirable for any clinical trial in AF.

KW - Anti-Arrhythmia Agents/therapeutic use

KW - Anticoagulants/therapeutic use

KW - Atrial Fibrillation/economics

KW - Catheter Ablation/methods

KW - Costs and Cost Analysis

KW - Electric Countershock/methods

KW - Electrocardiography

KW - Heart Failure/etiology

KW - Hospitalization

KW - Humans

KW - Quality of Life

KW - Randomized Controlled Trials as Topic

KW - Stroke/etiology

KW - Treatment Outcome

KW - Ventricular Dysfunction, Left/etiology

U2 - 10.1093/eurheartj/ehm358

DO - 10.1093/eurheartj/ehm358

M3 - SCORING: Journal article

C2 - 17897924

VL - 28

SP - 2803

EP - 2817

JO - EUR HEART J

JF - EUR HEART J

SN - 0195-668X

IS - 22

ER -